Evidence map›Paper›PMID 35815790›Full record

ArticleDrug delivery2022

Flexible nano-liposomes-based transdermal hydrogel for targeted delivery of dexamethasone for rheumatoid arthritis therapy.

Yi-Pu Zhao, Jiang-Fan Han, Fei-Yue Zhang, Tian-Tian Liao, Ren Na, Xiao-Feng Yuan, Guang-Bin He, Weiliang Ye

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Nanoparticle Delivery Systems in Rheumatoid Arthritis: More Than Vehicles.Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Yi-Pu ZhaoDepartment of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, China.
Jiang-Fan HanDepartment of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, China.
Fei-Yue ZhangDepartment of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, China.
Tian-Tian LiaoDepartment of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, China.
Ren NaDepartment of Epidemiology and Health Statistics, Faculty of Military Preventive Medicine, Fourth Military Medical University, Xi'an, China.
Xiao-Feng YuanDepartment of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, China.
Guang-Bin HeDepartment of Ultrasound Diagnosis, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Weiliang YeDepartment of Pharmaceutics, School of Pharmacy, Fourth Military Medical University, Xi'an, China.
Air Force Medical University · CNNorthwestern Polytechnical University · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is an inflammatory immune-mediated disease that can lead to synovitis, cartilage destruction, and even joint damage. Dexamethasone (DEX) is a commonly used agent for RA therapy on inflammation manage. However, the traditional administering DEX is hampered by low efficiency and obvious adverse effects. Therefore, in order to efficiently deliver DEX to RA inflamed joints and overcome existing deficiencies, we developed transdermal formation dextran sulfate (DS) modified DEX-loaded flexible liposome hydrogel (DS-FLs/DEX hydrogel), validated their transdermal efficiency, evaluated its ability to target activated macrophages, and its anti-inflammatory effect. The DS-FLs/DEX exhibited excellent biocompatibility, sustainable drug release, and high uptake by lipopolysaccharide (LPS)-activated macrophages. Furthermore, the DS-FLs/DEX hydrogel showed desired skin permeation as compared with regular liposome hydrogel (DS-RLs/DEX hydrogel) due to its good deformability. In vivo, when used the AIA rats as RA model, the DS-FLs/DEX hydrogel can effectively penetrate and accumulate in inflamed joints, significantly improve joint swelling in RA rats, and reduce the destructive effect of RA on bone. Importantly, the expression of inflammatory cytokines in joints was inhibited and the system toxicity did not activate under DS-FLs/DEX hydrogel treatment. Overall, these data revealed that the dextran sulfate (DS) modified DEX-loaded flexible liposome hydrogel (DS-FLs/DEX hydrogel) can prove to be an excellent drug delivery vehicle against RA.

Indexed as

Arthritis, RheumatoidDexamethasoneNanoparticle Drug Delivery SystemAdministration, CutaneousAnimalsBiocompatible MaterialsDextran SulfateDrug LiberationHydrogelsJointsLiposomesMaleMiceRatsRats, Sprague-DawleyRAW 264.7 CellsBiocompatible MaterialsDexamethasoneDextran SulfateHydrogelsLiposomesNanoparticle Drug Delivery Systemdextran sulfateflexible liposomerheumatoid arthritisTransdermal drug delivery system

Identifiers

PMID35815790
PMCPMC9275483
OpenAlexW4285007965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.